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Abstract
Background
T-type calcium channels (TTCCs) mediate calcium influx across the cell membrane. TTCCs
regulate numerous physiological processes including cardiac pacemaking and neuronal
activity. In addition, they have been implicated in the proliferation, migration and differentia-
tion of tumour tissues. Although the signalling events downstream of TTCC-mediated cal-
cium influx are not fully elucidated, it is clear that variations in the expression of TTCCs
promote tumour formation and hinder response to treatment.
Methods
We examined the expression of TTCC genes (all three subtypes; CACNA-1G, CACNA-1H
and CACNA-1I) and their prognostic value in three major solid tumours (i.e. gastric, lung
and ovarian cancers) via a publicly accessible database.
Results
In gastric cancer, expression of all the CACNA genes was associated with overall survival
(OS) among stage I-IV patients (all p<0.05). By combining the three potential biomarkers, a
TTCC signature was developed, which retained a significant association with OS both in
stage IV and stage I-III patients. In lung and ovarian cancer, association with OS was also
significant when all tumour stages were considered, but was partly lost or inconclusive after
splitting cases into localized and metastatic subsets.
Conclusions
Alterations in CACNA gene expression are linked to tumour prognosis. Gastric cancer rep-
resents the most promising setting for further evaluation.
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Introduction
Calcium is a universal cellular messenger that regulates a plethora of physiological events
including gene transcription, cell survival and cell proliferation [1,2]. Numerous studies have
shown that cellular calcium signalling is altered in cancer cells, although not all tumour types
show the same alterations in calcium signalling [3]. Changes in calcium signals affect cell pro-
liferation, apoptosis and metastatic potential [4].
Among the different calcium channels implicated in cancer, T-type calcium channels
(TTCCs) have been linked to tumour initiation and progression [3]. In particular, TTCCs trig-
ger cancer cell proliferation via the mitogen-activated kinase pathway [5], while TTCC inhibi-
tion induces cancer cell apoptosis [4]. Pharmacological TTCC inhibitors are being tested as
anti-cancer drugs in clinical trials [6]. Therefore, modulating calcium homeostasis via inhibi-
tion of TTCCs may be a promising strategy for cancer treatment, and this approach is under
early phase of development in several tumour types [7].
TTCCs consist of a calcium-conducting alpha subunit that forms a complex with a number
of other regulatory subunits. Three types of TTCC-alpha subunits have been identified
(named Cav3.1, Cav3.2 and Cav3.3), encoded by the genes CACNA-1G, CACNA-1H and
CACNA-1I [8]. Expression of the three CACNA genes varies in different tumour types, and
between normal tissue and the corresponding neoplastic counterpart [4]. In particular, no
study has investigated how variations in TTCC expression impact on patient prognosis, or
response to conventional treatments. Given the burgeoning evidence that suggests a causal
link between TTCC expression and tumour progression, it is critical to examine the utility of
TTCCs as a prognostic and therapeutic tool.
In order to explore the role of CACNA-1G, CACNA-1H and CACNA-1I in the clinical sce-
nario, we searched a publicly available database [9] and evaluated the association between
the expression of these genes and survival in different solid tumours represented on the
online platform (i.e. breast, gastric, lung and ovarian cancer). These tumours represent
unmet needs in clinical oncology, due to the inadequate therapeutic alternatives currently
available for the majority of patients, particularly in the advanced disease setting. Moreover,
many of the attempts made in the last years to improve the results of conventional chemo-
therapy by means of molecularly targeted drugs have disappointingly failed, as in the case of
gastric cancer [10]. Therefore, the identification of new promising prognostic biomarkers,
which may also represent specific and potent therapeutic targets, is a critical demand in
oncology.
Materials and methods
We analyzed data from the world’s largest collection of patients’ transcriptomic data for breast,
gastric, lung and ovarian cancer (Kaplan-Meier Plotter, accessible on: http://kmplot.com/
analysis/) [9]. We queried the database for expression of three TTCC-encoding genes:
CACNA-1G, CACNA-1H and CACNA-1I. For all tumour types, association between gene
expression and survival parameters available on the online platform was investigated. Survival
parameters used were the following: overall survival (OS) and survival without tumour pro-
gression for advanced (M1) cases (progression-free survival, PFS) or tumour recurrence for
non-metastatic (M0) cases (disease-free survival, DFS).
A log-rank test was used to correlate survival outcomes among subgroups identified by
gene expression, and the effect was estimated by means of hazard ratio (HR) and correspond-
ing 95% confidence interval (95%CI). The level of significance for single gene analyses was set
at p<0.05. Association with OS in the entire dataset of patients for each tumour types was ini-
tially tested. Cases were then categorized according to the most relevant prognostic variable
T-type calcium channels and tumour prognosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0182818 August 28, 2017 2 / 12
(i.e. tumour stage according to TNM classification [accessible on https://cancerstaging.org/
Pages/default.aspx]), separating metastatic cases (stage IV, M1) and potentially curable disease
(stage I-III, M0). For each single tumour type, other subgrouping of available data beyond dis-
ease stage was applied as appropriate, exploiting the variables available on the database. In
detail, for lung cancer, histology (adenocarcinoma versus squamous-cell carcinoma) was used,
whereas for ovarian cancer the quality of resection (optimal debulking surgery versus subopti-
mal debulking surgery) was selected. For breast cancer, different covariates were looked for to
adjust results and allow appropriate interpretation of the results (HER-2 status, hormone
receptors status, tumour grading, treatment received). However, as the database does not
allow sufficient patient stratification according to established prognostic and predictive param-
eters and information about the treatment administered is limited, we decided not to explore
the role of CACNA genes expression in breast cancer.
When results across the subgroups were found to be consistent, step-down correction was
applied to adjust for multiple tests. All the genes significantly associated with clinical outcome
after adjustment were combined to generate a TTCC gene signature, whose prognostic signifi-
cance was investigated across subgroups by means of the log-rank test and setting significance
at p<0.05.
In order to further elucidate the role of CACNA genes in solid tumours, the online database
of the Living Tumor Lab (Vancouver, BC, Canada) was queried (accessible on: http://www.
livingtumorlab.com/): the levels of CACNA expression in lung and ovarian cancer xenografts
from patient-derived samples was investigated (gastric cancer was not evaluable on the plat-
form, as no xenografts from gastric cancer patients has been developed yet). Patient-derived
sub-renal capsule xenografts were generated as described in previous publications [11,12].
Transcriptomic analyses, expressed as log base-2 (log2) microarray data, from these xenografts
were generated as described in the original paper [13] and are deposited at the Living Tumor
Lab website. The expression values for each gene were reported on a transformed log2 scale. A
Mann-Whitney test was used to compare different CACNA gene expression between meta-
static and non-metastatic xenografts.
Results
Gastric cancer
CACNA-1H was the single best predictor of clinical outcome (Table 1), showing significant
association with OS in both stage I-III (HR 2.27, 95%CI 1.62–3.20; p<0.001) and stage IV
(HR 1.8, 95%CI 1.22–2.67; p = 0.003) patients, with high expression associated with poorer
survival outcomes. When tested for association with DFS and PFS, CACNA-1H retained its
prognostic value (HR 2.03, 95%CI 1.47–2.80; p<0.001 and HR 1.62, 95%CI 1.10–2.39;
p = 0.013, respectively).
Expression of both CACNA-1G and CACNA-1I was associated with OS in all stage gastric
cancer patients, but with opposite effects in terms of survival (lower risk for higher CACNA-
1G expression, increased risk for higher CACNA-1I expression: HR 0.84, 95%CI 0.71–1.00;
p = 0.046 and HR 1.53, 1.28–1.82; p<0.001, respectively), even though the relationship with
outcome was less clear and unequivocal among different stages or in terms of DFS and PFS
(Table 1).
Moving from the results observed in stage IV disease, we selected the correlations that
retained statistical significance by step-down correction for multiple testing. Then, we gener-
ated a TTCC gene signature by combining all the three significant loci together and calculating
the value of (CACNA-1HCACNA-1I)/CACNA-1G for each patient included. Table 2 shows
T-type calcium channels and tumour prognosis
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the results of this analysis: our signature was highly significantly associated with OS, PFS and
DFS, in both metastatic and non-metastatic patients (all p<0.05).
In order to refine the role of the TTCC gene signature in gastric cancer, we also tested the
prognostic value of our signature in subgroups defined by: Lauren histotypes (intestinal, dif-
fuse), adjuvant treatment (surgery only, 5-fluorouracil-based adjuvant chemotherapy, other
chemotherapy) and HER-2 status (positive, negative). Subgroup analyses confirmed the role of
the developed gene signature in this setting, demonstrating that it could represent an indepen-
dent predictor of DFS/PFS (Fig 1A) and OS (Fig 1B).
Lung and ovarian cancer
Results for other malignancies are summarised in Supporting Information. With regard to
lung cancer (S1 Table), we queried CACNA-1G, CACNA-1H and CACNA-1I expression in ade-
nocarcinomas and squamous-cell carcinomas (operable and metastastic tumours. With regard
to OS, we observed an association similar to that reported in gastric cancer (increased risk for
higher CACNA-1H and CACNA-1I expression, reduced risk for higher CACNA-1G expression)
in the adenocarcinoma subset when all patients were included, whereas significance was
retained for CACNA-1H only in squamous-cell carcinoma. We attempted to explore the role
of these loci in stage I-III versus stage IV patients, but the results were less reliable due to the
limited subgroup size. In particular, among stage I-III patients only few cases had received a
radical (R0) tumour resection.
Table 2. Association of TTCC gene signature with outcome in gastric cancer.
Stage n DFS/PFS OS
FP/OS HR 95%CI p HR 95%CI p
all -/444 not applicable 1.75 1.47–2.09 <0.001
I-III, M0 443/444 2.00 1.43–2.80 <0.001 1.90 1.43–2.51 <0.001
IV 141/148 1.75 1.10–2.79 0.018 1.88 1.21–2.92 0.005
Abbreviations: n, number of patients (for first progression [FP] analysis–i.e. DFS and PFS—and OS analysis); DFS, disease-free survival; PFS,
progression-free survival; OS, overall survival; HR, hazard ratio; 95%CI, 95% confidence interval; p, p-value.
https://doi.org/10.1371/journal.pone.0182818.t002
Table 1. Association of CACNA-1G, CACNA-1H and CACNA-1I with outcome in gastric cancer.
Gene n Stage DFS/PFS OS
FP/OS HR 95%CI p HR 95%CI p
CACNA1G -/876 all not applicable 0.84 0.71–1.00 0.046
443/444 I-III, M0 0.84 0.63-1-13 0.250 0.85 0.62–1.15 0.290
141/148 IV 0.66 0.43–1.03 0.063 1.57 1.01–2.45 0.044
CACNA1H -/876 all not applicable 1.64 1.38–1.94 <0.001
443/444 I-III, M0 2.03 1.47–2.80 <0.001 2.27 1.62–3.20 <0.001
141/148 IV 1.62 1.10–2.39 0.013 1.80 1.22–2.67 0.003
CACNA1I -/876 all not applicable 1.53 1.28–1.82 <0.001
443/444 I-III, M0 1.59 1.17–2.15 0.003 1.60 1.19–2.14 0.002
141/148 IV 1.34 0.92–1.97 0.130 1.60 1.09–2.35 0.015
Abbreviations: n, number of patients (for first progression [FP] analysis–i.e. DFS and PFS—and OS analysis); DFS, disease-free survival; PFS,
progression-free survival; OS, overall survival; HR, hazard ratio; 95%CI, 95% confidence interval; p, p-value.
https://doi.org/10.1371/journal.pone.0182818.t001
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When ovarian cancer cases were considered, we observed an opposite trend for all CACNA
loci compared to gastric and lung adenocarcinoma (S2 Table): when all disease stages were
analyzed, higher expression of CACNA-1G seemed to increase the risk of death (HR 1.22, 95%
CI 1.07–1.40; p = 0.004), whereas higher expression of CACNA-1H and CACNA-1I reduced
the risk (HR 0.82, 95%CI 0.71–0.96; p = 0.011 and HR 0.84, 0.73–0.97; p = 0.018, respectively).
Globally considered, however, the effect seemed weaker compared to that observed in gastric
cancer. As quality of surgery is a key element in the prognosis of all ovarian cancer cases, par-
ticularly those with more advanced disease, we analyzed earlier stages (I-II) separately to
advanced ones (stage III-IV), restricting the analysis to stage III-IV patients with optimal
debulking surgery: as reported in S2 Table, the association with outcome was retained in some
comparisons, but none of the investigated genes retained its significant effect on all survival
endpoints (DFS/PFS and OS). Results did not change significantly when only patients treated
with platinum-containing chemotherapy were included in the analyses (S2 Table).
Fig 1. Association of the TTCC gene signature with outcome in gastric cancer: Subgroup analyses for
first progression (Fig 1A) and overall survival (Fig 1B). Abbreviations: HR (95%CI), hazard ratio (95%
confidence interval); p, p-value; 5-FU, 5-fluorouracil; CT, chemotherapy.
https://doi.org/10.1371/journal.pone.0182818.g001
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Transcriptomic analysis of CACNA-dependent pathways
To gain further insight into the molecular mechanisms underpinning the prognostic role of
CACNA genes, we performed a molecular network analysis, using the Cbio portal (stomach
adenocarcinoma database, 265 clinical samples) [14]. CACNA-1G was up-regulated in 25% of
these clinical samples (Z score>0), and it was associated with 51 interacting molecules (Fig
2A). In particular, it was predicted to be regulated by beta-catenin (CTNNB1) and in complex
with neural adhesion molecule (NCAM1). CACNA-1I (up-regulated in 25% of samples) was
part of a 29-node network, in association with NCAM1 (Fig 2B). CACNA-1H was also pre-
dicted to be modulated by PRKACA (Protein Kinase cAMP-Activated Catalytic Subunit
Alpha). The only prediction available for CACNA-1I (upregulated in 27% of samples) was the
association with NCAM1 (Fig 2C).
CACNA genes expression in patient-derived cancer tissue xenografts
In order to confirm the expression of CACNA genes in an independent dataset, we analysed
transcriptomic data from high-fidelity patient-derived xenografts. Results for lung and ovarian
cancer are summarized in S1 and S2 Figs, respectively. With regard to lung cancer, no appar-
ent relevant differences among the different CACNA loci was evident, with the exception of
CACNGA-1H which was highly expressed in two samples (L347 and L613), differing for histol-
ogy (adenocarcinoma and squamous-cell carcinoma, respectively) and clinical stage (stage IV
and IIIA respectively). When metastatic xenografts were compared with non-metastatic ones,
higher CACNA-1I expression was evident in the first subset (p = 0.022) (S3 Fig). Among the
available ovarian cancer xenografts, no gross imbalances in the expression of candidate genes
were reported. The only differences were observed for CACNA-1H (whose expression was
higher in two samples: LTL-175 and LTL-307) and CACNA-1I (which appeared to be more
expressed in two samples: LTL-237 and LTL-273). However, when metastatic and non-meta-
static ovarian cancer xenografts were compared, no difference in expression was reported for
any CACNA gene evaluated (all p>0.05).
Discussion
TTCCs were identified in the 1980s by Tsien and colleagues, and have tissue expression pat-
terns and biophysical characteristics that distinguish them from other voltage-operated Ca2+
Fig 2. Network analyses for CACNA1G (A), CANA1H (B) and CACNA1I (C). Red color is more intense
when associated with higher percentage of up-regulation in cancer samples. Blue lines mean: “controls the
state change of”; green lines mean: “controls the expression of”; brown lines mean: “in complex with”.
https://doi.org/10.1371/journal.pone.0182818.g002
T-type calcium channels and tumour prognosis
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channels [15,16]. In particular, they can be activated by relatively small membrane depolarisa-
tions. Hence, the term ‘low voltage activated channels’ is often used to describe them. The
functional consequence of this characteristic is that the voltage range for activation overlaps
with that for inactivation, which is close to the resting membrane of most cells, giving the
potential for sub-populations of TTCCs to be perpetually active and drive a constitutive Ca2+
influx current that is sometimes referred to as a ‘window current’ [17].
TTCCs have been proposed to be involved in action potential bursting in neurons, endo-
crine cell secretion, pacemaking activity in the heart, as well as in pathological conditions such
as epilepsy and autism [18]. Moreover, numerous reports have correlated the expression of
TTCCs with proliferation of tumour cells [19,20,21,22].
Our analyses suggest for the first time that a TTCC gene signature accurately predicts the
prognosis of gastric cancer patients, both in the radically resectable and metastatic disease.
Moreover, some of these TTCC-related genes may play a role in ovarian cancer, although the
overall magnitude of effect seems lower compared to gastric cancer. Taken together, these data
confirm that monitoring CACNA-1G, CACNA-1H and CACNA-1I expression in solid tumours
may be an intriguing approach to refine patient stratification and hopefully identified new
therapeutic targets. As the identification of innovative prognostic and predictive biomarkers is
a major need in modern oncology, the preliminary evidence of a putative impact of CACNA
genes expression on patient survival both in the advanced and in the potentially curative set-
tings prompts further research on the biological mechanisms behind TTCCs functions in solid
tumours. Indeed, accurately predicting patient prognosis allows for a more rationale study
design and treatment allocation, as well as identifying new potential targets for anticancer
treatment open the way to hypothesize a personalized approach in the development of calcium
channels inhibitors.
In the gastric cancer subset of a large, public database of transcriptomic data the gene signa-
ture described by (CACNA-1HCACNA-1I)/CACNA-1G was associated with both OS and
DFS/PFS, even in subgroups defined by tumour stage, HER-2 expression, type of adjuvant che-
motherapy and Lauren histology. These findings deserve further confirmation in larger, pro-
spectively collected series treated with homogenous local and systemic treatments. Our
analysis shares the limitations of any retrospective investigation, potentially biased by different
confounding factors. Moreover, the platform did not allow for appropriate patient stratifica-
tion by quality of surgery in resected cases and type of chemotherapy among metastatic
patients. Therefore, we cannot exclude a potential impact of other known determinants of
prognosis beyond TTCC genes. However, the concordance of the findings in several sub-
groups defined by the covariates available on KMPlot prompts in our opinion the evaluation
of this putative biomarker in this specific tumour type.
With regard to other malignancies available for analyses, some considerations need to be
kept in mind in the interpretation of the results. For ovarian cancer, CACNA-1G, CACNA-1H
and CACNA-1I all showed a significant association with OS when all the cases were included
in the analysis, but the direction of the effect was exactly the opposite of that shown in gastric
cancer. For some of the comparisons, significance was retained also after adjustment for
tumour stage, quality of surgery and type of chemotherapy. Other known prognostic factors
are available on the platform (i.e. grade, histology, CA125 levels), but the number of cases
would have been too limited with stricter selection criteria. Data from patient-derived xeno-
grafts highlighted some variations in CACNA expression among samples, particularly for
CACNA-1H and CACNA-1I, which are both clinically associated with a reduction in the risk of
death according to KMPlot analyses.
TTCC genes also showed some significant association with OS in lung cancer, in particular
in the adenocarcinoma subset, and the observed direction of the effect of expression of
T-type calcium channels and tumour prognosis
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CACNA-1G, CACNA-1H and CACNA-1I was in the same way to that reported in gastric can-
cer. However, other factors (mainly related to driver gene alterations in lung cancer, such as
EGFR and ALK) were not reported, as well as the information about treatment with targeted
therapy for oncogene-addicted tumours (which may confound the results in the adenocarci-
noma subset). Data from the Living Tumor Lab platform revealed that some xenografts
showed particularly high CACNA1H expression, but no correlation seems to exist between this
parameter and clinical (e.g. stage) or pathological (e.g. histology) features.
Our network analysis indicates that the 3 CACNA genes are associated with partially over-
lapping, but distinct molecular networks. Interestingly, all 3 CACNAs were predicted to inter-
act closely with NCAM1, which has been positively associated with gastric cancer progression
[23]. Notably, NCAM1 has been shown to trigger intracellular signalling via TTCCs in neu-
rons [24]. It would be interesting to see if NCAM1 plays a similar role in gastric and other neo-
plasms. CACNA1G was associated with the most complex molecular network, which included
several G-proteins and CTNNB1, a proto-oncogene that drives gastric cancer cells’ epithelial-
to-mesenchymal transition [25]. We believe that these network analyses shed new light on the
specific contribution of each CACNA gene to neoplastic progression. Further molecular stud-
ies are needed to dissect the specific role of each of these molecular pathways. In particular,
studies are needed to establish that calcium signals, arising via functional TTCC activation, are
actually mediating the effects of CACNA gene expression on neoplastic progression. Since cal-
cium channels often work in macromolecular assemblies within cells, it is possible that there
are both calcium-dependent and calcium-independent signalling partners for TTCCs. More-
over, future insights into TTCC-related pathways may pave the way toward a more rationale
preclinical and clinical development for agents targeting calcium homeostasis via TTCCs
inhibition.
Blocking TTCC activity with an endogenous protein [26], siRNA-based/RNAi knockdown
[5,22,27,28,29,30] or pharmacological inhibitors [22,28,30,31,32,33] has been shown to reduce
cancer cell proliferation and migration. Furthermore, inhibiting TTCCs enhances the effec-
tiveness of conventional anti-cancer chemotherapeutic agents [4].
Many studies have used pharmacological inhibitors, such as the compounds mibefradil,
NNC-55-0396, KYS05090 and pimozide, to investigate the role of TTCCs in tumour cell prolif-
eration. These compounds have been shown to prevent proliferation of various types of
tumour cells, with effective concentrations in the low micromolar range [31]. Inhibitors of
‘high voltage activated channels’, such as the L-type Ca2+ channel blocker nifedipine, do not
share the anti-proliferative potency of TTCC antagonists [28]. Although some studies have
indicated that pharmacological TTCC blockers may affect cell proliferation via off-target
effects, there is considerable evidence from other approaches that substantiates the involve-
ment of TTCCs in tumour cell growth. For example, RNAi-mediated reduction of TTCC
expression was found to inhibit the proliferation of tumour cells in which a bona fide T-type
Ca2+ current was also demonstrated, but not in tumour cells that did not have a T-type Ca2+
current [27]. In addition, oral administration of mibefradil to mice bearing gliobastoma xeno-
grafts was found to inhibit tumour growth and prolong survival of the host animals [22].
Despite numerous studies showing that inhibiting or downregulating TTCCs affects
tumour cell proliferation, the molecular events leading from reduced TTCC activity to inhibi-
tion of cell growth are unclear [4]. Indeed, the reported cellular effects of reduced TTCC activ-
ity are widely disparate and include cell cycle arrest [32,29], induction of necrosis [31],
increased p21CIP1 expression [27], apoptotic cell death [5,21,32], reduced mTORC2/Akt sig-
nalling [22,28], and stimulation of p38 MAP kinase activity [5]. Whilst there is still more to
discover before a full understanding of the role of TTCCs in cancer cell proliferation is estab-
lished, the burgeoning literature on this topic has provoked suggestions that TTCCs blockers
T-type calcium channels and tumour prognosis
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designed for other functions could be repurposed for cancer therapy [34]. While waiting for
these insights into TTCC-mediated mechanisms of tumour progression, our signature could
serve as a promising instrument to drive research into the tailored development of Ca2+ chan-
nels-targeting agents and deserves further validarion, at least in gastric cancer.
In conclusion, our results are in line with preclinical data supporting the role of TTCCs in
tumour progression and suggest a potential role of TTCC genes in predicting patient outcome
in the clinical scenario. On the basis of the investigated platforms, gastric cancer represents a
promising setting for the prospective validation of these findings. More studies examining the
link between TTCC gene expression and tumour progression are needed, in addition to inves-
tigations into the cellular consequences of TTCC expression in tumour cells to develop thera-
peutic targets.
Supporting information
S1 Table. Association of CACNA-1G, CACNA-1H and CACNA-1I with outcome in lung
cancer. Abbreviations: n, number of patients (for first progression [FP] analysis–i.e. DFS and
PFS—and OS analysis); DFS, disease-free survival; PFS, progression-free survival; OS, overall
survival; HR, hazard ratio; 95%CI, 95% confidence interval; p, p-value; only R0-resected cases
included.
(PDF)
S2 Table. Association of CACNA-1G, CACNA-1H and CACNA-1I with outcome in ovar-
ian cancer. Abbreviations: n, number of patients (for first progression [FP] analysis–i.e. DFS
and PFS—and OS analysis); DFS, disease-free survival; PFS, progression-free survival; OS,
overall survival; HR, hazard ratio; 95%CI, 95% confidence interval; p, p-value; only cases with
optimal debulking surgery included.
(PDF)
S1 Fig. Expression levels of different CACNA (transformed log2) from microarray analysis
of patient-derive lung cancer xenografts. Abbreviations: NOS, not otherwise specified.
TNM stage refers to tumour stage in the original patient: all xenografts were derived from pri-
mary lung tumours without distant metastases (M0), with the only exception of L347 (derived
from a metastatic lung tumour, M1).
(TIF)
S2 Fig. Expression levels of different CACNA (transformed log2) from microarray analysis
of patient-derive ovarian cancer xenografts. Abbreviations: Histology refers to tumour type
in the original patient: all xenografts were derived from primary ovarian tumours.
(TIF)
S3 Fig. Expression levels of CACNA1I (transformed log2) from microarray analysis of
patient-derive lung cancer xenografts (metastatic vs. non-metastatic).
(TIF)
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